(METN) Metall Zug - Ratings and Ratios
Medical Devices, Diagnostics Equipment, Cleaning Equipment, Real Estate
Description: METN Metall Zug
Metall Zug AG is a diversified industrial conglomerate with a presence in multiple geographies, operating through various subsidiaries across different business segments, including medical devices, infection control, technology, and infrastructure, as well as real estate development and management.
The companys medical devices segment is a significant contributor, offering a range of products and solutions for medical diagnosis, microsurgery, and eye care, including slit lamps, perimetry and biometry equipment, and high-precision surgical microscopes. The technology is also being adapted for augmented reality applications, indicating a potential growth area.
From a financial perspective, Metall Zug AG has a market capitalization of approximately 472.92 million CHF, with a relatively low Price-to-Earnings (P/E) ratio of 9.03, suggesting the stock may be undervalued. The Return on Equity (RoE) of 17.07% indicates a decent level of profitability. To further evaluate the companys performance, other key performance indicators (KPIs) such as Revenue Growth, EBITDA Margin, and Debt-to-Equity ratio would be essential.
Assuming the companys diversified business segments and geographic presence provide a stable foundation, a deeper analysis of its segment-wise revenue contribution, operating margins, and cash flow generation would be necessary to assess its long-term sustainability and potential for growth. Additionally, evaluating the companys competitive positioning within its respective markets and its ability to innovate and adapt to changing market conditions would be crucial.
With a history dating back to 1887, Metall Zug AG has established itself as a reputable player in its respective markets. Its commitment to innovation, as evident from its augmented reality technology and digital imaging solutions, may be a key driver of future growth. A thorough analysis of the companys research and development (R&D) expenses, patent portfolio, and new product pipeline would provide further insights into its growth prospects.
METN Stock Overview
| Market Cap in USD | 544m |
| Sub-Industry | Industrial Conglomerates |
| IPO / Inception |
METN Stock Ratings
| Growth Rating | -45.5 |
| Fundamental | 58.6% |
| Dividend Rating | 47.2 |
| Rel. Strength | -34.8 |
| Analysts | - |
| Fair Price Momentum | 866.23 CHF |
| Fair Price DCF | - |
METN Dividends
| Dividend Yield 12m | 1.96% |
| Yield on Cost 5y | 1.79% |
| Annual Growth 5y | 11.73% |
| Payout Consistency | 91.4% |
| Payout Ratio | 17.1% |
METN Growth Ratios
| Growth Correlation 3m | -81.7% |
| Growth Correlation 12m | -81.3% |
| Growth Correlation 5y | -62.2% |
| CAGR 5y | -2.69% |
| CAGR/Max DD 5y | -0.05 |
| Sharpe Ratio 12m | -0.19 |
| Alpha | -31.76 |
| Beta | 0.409 |
| Volatility | 22.04% |
| Current Volume | 0.1k |
| Average Volume 20d | 0.2k |
| Stop Loss | 946.7 (-3%) |
| Signal | -0.85 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (74.8m TTM) > 0 and > 6% of Revenue (6% = 46.7m TTM) |
| FCFTA -0.05 (>2.0%) and ΔFCFTA -1.05pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 0.30% (prev 16.38%; Δ -16.08pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.03 (>3.0%) and CFO 20.4m <= Net Income 74.8m (YES >=105%, WARN >=100%) |
| Net Debt (65.7m) to EBITDA (89.4m) ratio: 0.74 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.02 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (450.0k) change vs 12m ago NaN% (target <= -2.0% for YES) |
| Gross Margin 31.18% (prev 35.09%; Δ -3.92pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 117.6% (prev 93.53%; Δ 24.05pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.29 (EBITDA TTM 89.4m / Interest Expense TTM 12.9m) >= 6 (WARN >= 3) |
Altman Z'' 1.53
| (A) 0.00 = (Total Current Assets 129.5m - Total Current Liabilities 127.2m) / Total Assets 633.0m |
| (B) 0.09 = Retained Earnings (Balance) 59.0m / Total Assets 633.0m |
| (C) 0.10 = EBIT TTM 68.3m / Avg Total Assets 661.8m |
| (D) 0.48 = Book Value of Equity 70.2m / Total Liabilities 146.5m |
| Total Rating: 1.53 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 58.63
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield -6.19% = -3.09 |
| 3. FCF Margin -4.00% = -1.50 |
| 4. Debt/Equity 0.20 = 2.48 |
| 5. Debt/Ebitda 0.93 = 1.87 |
| 6. ROIC - WACC 6.65% = 8.31 |
| 7. RoE 17.07% = 1.42 |
| 8. Revenue Trend data missing |
| 9. Rev. CAGR -30.37% = -2.50 |
| 10. EPS Trend data missing |
| 11. EPS CAGR 21.35% = 2.14 |
What is the price of METN shares?
Over the past week, the price has changed by -3.84%, over one month by -5.24%, over three months by -9.63% and over the past year by -21.69%.
Is Metall Zug a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of METN is around 866.23 CHF . This means that METN is currently overvalued and has a potential downside of -11.25%.
Is METN a buy, sell or hold?
What are the forecasts/targets for the METN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 1138 | 16.6% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 950.9 | -2.6% |
METN Fundamental Data Overview
Market Cap CHF = 437.5m (437.5m CHF * 1.0 CHF.CHF)
CCE Cash And Equivalents = 17.1m CHF (last quarter)
P/E Trailing = 8.3504
P/S = 1.5437
P/B = 1.0415
Beta = 0.829
Revenue TTM = 778.1m CHF
EBIT TTM = 68.3m CHF
EBITDA TTM = 89.4m CHF
Long Term Debt = unknown (0.0)
Short Term Debt = 82.8m CHF (from shortTermDebt, last quarter)
Debt = 82.8m CHF (Calculated: Short Term 82.8m + Long Term 0.0)
Net Debt = 65.7m CHF (from netDebt column, last quarter)
Enterprise Value = 503.3m CHF (437.5m + Debt 82.8m - CCE 17.1m)
Interest Coverage Ratio = 5.29 (Ebit TTM 68.3m / Interest Expense TTM 12.9m)
FCF Yield = -6.19% (FCF TTM -31.1m / Enterprise Value 503.3m)
FCF Margin = -4.00% (FCF TTM -31.1m / Revenue TTM 778.1m)
Net Margin = 9.61% (Net Income TTM 74.8m / Revenue TTM 778.1m)
Gross Margin = 31.18% ((Revenue TTM 778.1m - Cost of Revenue TTM 535.5m) / Revenue TTM)
Tobins Q-Ratio = 7.17 (Enterprise Value 503.3m / Book Value Of Equity 70.2m)
Interest Expense / Debt = 2.85% (Interest Expense 2.36m / Debt 82.8m)
Taxrate = 8.29% (from yearly Income Tax Expense: 4.78m / 57.6m)
NOPAT = 62.7m (EBIT 68.3m * (1 - 8.29%))
Current Ratio = 1.02 (Total Current Assets 129.5m / Total Current Liabilities 127.2m)
Debt / Equity = 0.20 (Debt 82.8m / last Quarter total Stockholder Equity 419.2m)
Debt / EBITDA = 0.93 (Net Debt 65.7m / EBITDA 89.4m)
Debt / FCF = -2.66 (Debt 82.8m / FCF TTM -31.1m)
Total Stockholder Equity = 438.2m (last 4 quarters mean)
RoA = 11.82% (Net Income 74.8m, Total Assets 633.0m )
RoE = 17.07% (Net Income TTM 74.8m / Total Stockholder Equity 438.2m)
RoCE = 15.59% (Ebit 68.3m / (Equity 438.2m + L.T.Debt 0.0))
RoIC = 13.39% (NOPAT 62.7m / Invested Capital 468.0m)
WACC = 6.74% (E(437.5m)/V(520.3m) * Re(7.52%)) + (D(82.8m)/V(520.3m) * Rd(2.85%) * (1-Tc(0.08)))
Shares Correlation 5-Years: 86.60 | Cagr: 0.08%
Discount Rate = 7.52% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -31.1m)
Revenue Correlation: N/A | Revenue CAGR: -30.37%
Revenue Growth Correlation: -99.82%
EPS Correlation: N/A | EPS CAGR: 21.35%
EPS Growth Correlation: 12.78%